Clarify the Role of Vivjoa for Recurrent Yeast Infections

September 2022

New oral Rx Vivjoa (oteseconazole) will be the first med approved for managing recurrent vulvovaginal candidiasis.

But this azole is only for patients with 3 or more yeast infections per year who are postmenopausal or permanently infertile.

Vivjoa is teratogenic in animals...and can stay in the body for up to 2 YEARS. So for now, it shouldn’t be used in ANY patient of childbearing potential, even those on contraceptives.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Influenza Know What’s Changed With Flu Immunization for 2022-2023
Infectious Diseases Educate About Monkeypox...and Limit Misinformation
Heart Failure Avoid Clinical Inertia in Patients With HFrEF and CKD
Oral Health Stick With Simple Approaches for Dry Mouth
Interactions Know Which Serotonin Syndrome Alerts Require a Med Change
Devices Be Ready to Answer Questions About Hearing Aids
Antithrombotics Demystify Gastroprotection With Antithrombotics
Vaginal Infections Clarify the Role of Vivjoa for Recurrent Yeast Infections
Diabetes Focus on Lifestyle and Insulin for Gestational Diabetes
Substance Use Disorder Assess Phenobarbital Use for Alcohol Withdrawal
Appropriate Med Use Address SGLT2 Inhibitor Use in the Hospital
Critical Care Sort Out Safe Treatment for Acute DIC

Clarify the Role of Vivjoa for Recurrent Yeast Infections

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents